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Abstract
A prospective observational study was conducted to examine whether asymptomatic VZV reactivation occurs in immunocompetent
children hospitalized in an ICU and its impact on clinical outcome. A secondary aim was to test the hypothesis that vaccinated children have
a lower risk of reactivation than naturally infected children. Forty immunocompetent paediatric ICU patients and healthy controls were
enrolled. Patients were prospectively followed for 28 days. Clinical data were collected and varicella exposure was recorded. Admission
serum levels of TNF-a, cortisol and VZV-IgG were measured. Blood and saliva samples were collected for VZV-DNA detection via real-time
PCR. As a comparison, the detection of HSV-DNA was also examined. Healthy children matched for age and varicella exposure type
(infection or vaccination) were also included. VZV reactivation was observed in 17% (7/39) of children. Children with VZV reactivation had
extended duration of fever (OR = 1.17; 95% CI, 1.02–1.34). None of the varicella-vaccinated children or healthy controls had detectable
VZV-DNA in any blood or saliva samples examined. HSV-DNA was detected in saliva from 33% of ICU children and 2.6% of healthy
controls. Among children with viral reactivation, typing revealed wild-type VZV and HSV-1. In conclusion, VZV reactivation occurs in
immunocompetent children under severe stress and is associated with prolonged duration of fever.
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Introduction
Varicella zoster virus (VZV) is a member of the alpha herpes-
virus subfamily. In primary infection, varicella, has low
morbidity and mortality rates in immunocompetent children
and induces long-lasting immunity [1]. Higher rates are
observed in infants, adults and immunocompromised patients
[1]. During primary infection the virus establishes latency in
sensory ganglia. Viral reactivation results in herpes zoster
(HZ), characterized by a painful dermatomal rash, the
frequency of which increases with age or reduced cellular
immunity [2]. While VZV-DNA is readily detectable in blood
and saliva of patients with recent HZ, it is less often detected
in asymptomatic immunocompromised patients and healthy
elderly individuals [3–5]. Both VZV-DNA and viable virus
have been detected in the saliva of healthy astronauts during
and after space ﬂights, supporting the notion that
asymptomatic VZV reactivation may occur in response to
stress [6,7].
It is not known whether asymptomatic VZV reactivation
occurs under stress among intensive care unit (ICU) patients.
A prospective study was conducted to evaluate whether
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children requiring intensive care have a greater likelihood of
presenting with asymptomatic VZV reactivation.
Materials and Methods
Study design
A prospective study was conducted in the paediatric ICU of a
tertiary children’s hospital during 2008 and 2009 and in healthy
paediatric outpatients. The study was approved by the hospital
ethics committee and written informed consent for study
participation was obtained from the legal guardians upon study
enrollment.
Study population
Children aged >12 months, admitted to the ICU, were eligible
for inclusion. Exclusion criteria included expected survival
<72 h, expected ICU stay <48 h, and known immunodeﬁ-
ciency or long-term therapy with steroids or other immuno-
suppressive agents. All children enrolled were screened for the
presence of VZV-IgG antibodies. All children’s immunization
cards were reviewed. Past natural infection or varicella
vaccination were noted. Unvaccinated children without doc-
umentation of previous varicella infection and with no
detectable VZV serum antibodies were considered unexposed
to VZV and therefore excluded from further analyses.
Study participants were prospectively evaluated for 28 days
following ICU admission. Children discharged prior to day 28 of
hospitalization were contacted by phone to record patient
outcome. Standardized data collection forms, including infor-
mation on interventions, medications and complications, were
used during their hospitalization (ICU and ward). A brief
questionnaire and patients’ immunization cards were used to
obtain demographic characteristics, as well as prior history of
varicella disease or vaccination, respectively. To preserve
anonymity all patient data and samples were coded. Upon
hospital admission the PRISM III scale was used to assess clinical
severity [8]. Serum samples were also obtained to measure
TNF-a and cortisol levels, as well as to assess pre-existing VZV
and herpes simplex virus (HSV) immunity. Peripheral whole
blood samples were obtained on a weekly basis until the date of
hospital discharge and stored at 35°C. Saliva samples were
obtained twice weekly during the same time period using special
synthetic swabs (Salivetta–Salivette, Sarsted). Enrolled chil-
dren in the ICU were also examined for the presence of HSV-1-
DNA, because HSV-1 is known to reactivate under stress [9].
Control group
Healthy children were examined for the presence of VZV and/
or HSV-1-DNA in blood and saliva samples. Parents of
controls were asked to provide written informed consent.
Children matched (1:1) for age and varicella exposure (natural
infection, vaccination, neither) with the ICU study population
were sampled once upon presentation at the outpatient
department for routine examination.
Serology testing
Prior immunity to VZV (either natural or vaccine related) and
HSV was investigated using the commercially available enzyme-
linked immunosorbent assays (ELISA), including Enzygnost
Anti-VZV/IgG (Siemens, Marburg, Germany) and Herpes
Simplex 1 ELISA IgG/IgM (gG1 recombnant) (Vircell SL, Santa
Fe, Spain) according to the manufacturer’s instructions. TNF-a
serum levels were quantiﬁed by the Elisa technique (Bender
MedSystems, GmbH, Vienna, Austria) in accordance with the
manufacturer’s instructions. Serum cortisol concentration was
measured in samples collected in the morning after fasting and
stored at 85°C, using an electrochemiluminescence immuno-
assay (Roche Co., Basel, Switzerland) according to the
manufacturer’s protocol.
DNA extraction and PCRs
DNA was extracted from 200 lL of either whole blood or
saliva using a QIAamp DNA Blood Mini Kit (Qiagen Ltd,
Crawley, West Sussex, UK) according to the manufacturer’s
instructions. Ampliﬁcation of VZV-DNA was performed using
a quantitative real-time PCR assay with a sensitivity of log10
0.4 genome copies (gc) per lL (10 copies/lL) as described
previously [10]. The presence of VZV-DNA was further
conﬁrmed using an in-house biallelic real-time PCR assay
targeting SNP 108111 in ORF 62, which distinguishes wild-
type and vaccine strains [10,11]. Ampliﬁcation of HSV-1 and
HSV-2-DNA was achieved using in-house real-time PCR
assays. To ensure sample integrity, PCR ampliﬁcation of the
human b-actin gene was performed. The laboratory was
blinded to the origin of the samples. In both ICU patients and
controls, the detection of viral DNA in either a blood or
saliva sample was deﬁned as viral reactivation.
Statistical analysis
Categorical variables were compared between groups using
the chi-squared test. Fisher’s exact test was used where cell
sizes did not exceed ﬁve patients. The Mann–Whitney U-test
was used to compare mean values of continuous variables
between groups. Spearman and Pearson correlations were
carried out to assess the correlation between categorical and
continuous variables, respectively, and the outcomes of
interest. Univariate logistic regression was used to calculate
odds ratios (ORs) and 95% conﬁdence intervals (95% CIs) for
evaluating the association between all independent variables
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examined (i.e. age, fever duration, anti-tnf levels, cortisol
levels, intubation, and days in ICU) and the occurrence of VZV
reactivation (yes vs. no) and HSV reactivation (yes vs. no).
Stepwise multivariate regression analysis was applied to
evaluate the association between the aforementioned factors
and VZV reactivation. A p-value of 0.05 was used as the
criterion of signiﬁcance. All statistical analyses were performed
using SAS v9.2 (SAS Institute, USA).
Results
Patient demographics and serological status
The study population consisted of 40 children (23 boys) with a
mean age (SD) of 9.04  4.28 years (range, 1.1–16.3 years).
Expected short ICU stay was the most common exclusion
criterion. Most participants (n = 27) were admitted due to
trauma or following surgery, while 13 children were admitted
for medical reasons. Admission PRISM III score was lower in
children admitted for medical reasons (6.5  4.4 vs. 9.9  5,
p 0.027). Most children (27/40, median age 11 years) had a past
history of varicella 0.3–12 years before admission (median
time 7 years). Of those, only 11 (40.7%) had the diagnosis of
chickenpox noted in their immunization cards. Six children
(median age, 3.8 years) had documented immunization against
varicella (median 2 years before admission) with a single
varicella vaccine dose, while parents of seven unvaccinated
children (median age 4.3 years) did not recall varicella infection
in their child. The majority of children (35/40) had detectable
VZV-IgG levels. Of the remaining ﬁve VZV-negative children,
two had documented vaccination and another two had had
chickenpox diagnosed by a paediatrician. A 3-year-old unvac-
cinated child with negative history of varicella was considered
unexposed to VZV and therefore excluded from the analysis.
Thus, 6/7 unvaccinated children with a negative history of
chickenpox had detectable VZV antibodies and were assumed
to have had subclinical natural infection. Hence, 39 children
admitted to the ICU were evaluated. Overall, 23/39 children
included in the analysis had detectable IgG antibodies against
HSV.
Detection of viral DNA in ICU children and healthy controls
Detection of VZV-DNA in ICU children. Varicella zoster virus
DNA was detected in the saliva and/or blood of 7/39 (17.9%)
children (four boys) hospitalized in the ICU (Table 1). Three
children were admitted for medical reasons. In ﬁve cases
where typing was possible, the viral DNA was conﬁrmed as
wild type. Two children who had VZV-DNA detected in the
blood and had subsequent blood samples available for testing,
were then negative for viral DNA. None of the participants
with detectable VZV-DNA had clinical signs of VZV infection
at the time of sampling or during the follow-up period of
28 days. None of six vaccinated children were VZV-DNA
positive, as compared with 4/27 (14.8%) seropositive children
with a history of varicella and 3/6 (50%) seropositive children
with no history of chickenpox. There were no differences in
overall frequency of sampling in the three groups (Table 2).
VZV-DNA was detected in 3/11 and 3/51 whole blood samples
obtained from children with past subclinical varicella and past
symptomatic varicella infection, respectively (p 0.06) (Table 2).
There was no difference in VZV-DNA detection between
children with past varicella (both symptomatic and subclinical)
and vaccinated children (7/33 vs. 0/6, p 0.278), nor in the
frequency of VZV-DNA detection in blood and saliva in these
groups.
Neither of the children with VZV present in saliva had been
intubated. Although mean time to ﬁrst detection of VZV was
6.6 days (range 1–15 day), three children had VZV-DNA
present in the initial sample collected within 24 h of admission
to the ICU; two in blood and one in saliva. Two were after
scheduled surgery (lumbar body fusion and benign cerebral
tumour) and the third after trauma.
Detection of HSV-DNA in ICU children. Overall, HSV-DNA was
detected in saliva from 13 children (33.3%), with a mean time
to detection of 3.4 days (1–9 days) following admission to the
ICU. HSV-DNA was detected signiﬁcantly more frequently
than VZV-DNA (13/39 children vs. 7/39, p 0.039). HSV-1-
DNA was not detected in any blood samples but was
signiﬁcantly more frequently detected in saliva samples
obtained from children admitted for medical reasons (11/38
vs. 9/93, p 0.005). Detection of both VZV and HSV in the same
patient was never observed. In six children HSV-1-DNA was
recovered in saliva obtained within 24–36 h of ICU admission,
with viral loads ranging from log10 5.0 gc/mL to log10 12.3 gc/
mL. No further HSV was detected in one or more salivary
samples taken subsequently from ﬁve of the six children. One
child continued to have detectable HSV in three further
samples and overall HSV-DNA was detected in multiple
samples, obtained over 7–9 days after ICU admission, in 3/13
children. Detection of HSV-1 antibodies was poorly predictive
of reactivation (PPV = 34.8%).
Detection of VZV or HSV-DNA among controls. As with the
study population, 6/39 healthy children were VZV IgG-
positive despite a negative/unknown history of exposure.
HSV serology was not evaluated in control children. No
control child had VZV-DNA in blood or saliva (0/39 vs. 7/39
children in the study population, p 0.012). HSV-DNA was
not detected in any blood sample obtained from healthy
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controls but was present in saliva from one (2.6%) control
child.
Risk factors for viral reactivation in ICU children
Demographic, clinical and laboratory data upon admission
were similar between children with and without VZV reacti-
vation (Table 3). Children admitted to the ICU for manage-
ment of medical conditions (mainly severe infections, sepsis)
were more likely to be positive for any viral DNA in either
blood or saliva samples than children admitted for surgical
interventions (p 0.08).
HSV-1-DNA was signiﬁcantly more often detected in saliva
samples collected from children admitted to the ICU for
medical management (11/38 saliva samples) compared with
those collected from children admitted after surgery or
trauma (9/93 saliva samples, p 0.005). VZV-DNA was also
more often detected in blood samples in medical patients (3/25
vs. 3/49) but this difference did not reach statistical signiﬁcance
(p 0.39).
By univariate regression analysis, VZV reactivation, but not
viral load, was associated with a prolonged course of fever
(>38°C axillary) during hospitalization (11.7 vs. 3.5 days; OR,
1.17; 95% CI, 1.02–1.34) and this association remained
signiﬁcant in multivariate analysis (AOR, 1.17; 95% CI, 1.01–
1.37). Although VZV-DNA detection was signiﬁcantly
associated with elevated cortisol levels upon admission (Wald
p-value, 0.04), this association was not signiﬁcant in multivar-
iate analysis (AOR, 1.00; 95% CI, 1.00–1.01).
Discussion
The results from this study showed that half of the children
(20/39) admitted to the ICU had reactivated alpha herpes-
viruses over a 28-day period. HSV-1 reactivation is well
recognized [12]. However, this is the ﬁrst time that VZV-DNA
detection, consistent with subclinical VZV reactivation, is
described among immunocompetent children under severe
stress (7/39, 17.9%). Of note, VZV-DNA was not detected in
any of the healthy controls (p 0.016).
Varicella zoster virus DNA was mainly detected in blood
samples. While VZV-DNA in the blood may not necessarily
represent circulating virus, the data supports the likelihood
TABLE 2. Patients’ VZV exposure and detection of VZV-
DNA in blood and saliva samples
N
Varicella
infection
(N = 27)
Varicella
vaccine
(N = 6)
Negative
history
(N = 6) p-valuea
VZV-DNA
shedding
in ICU
children
39 4/27 (14.8%) 0/6 3/6 (50%) 0.09
VZV-DNA(+)
blood samples
74 3/51 (5.9%) 0/12 3/11 (27.3%) 0.06
VZV-DNA(+)
saliva samples
131 1/93 (0.01%) 0/18 1/20 (5%) 0.32
aFisher’s exact test p-value for the comparison between children with primary
varicella infection and seropositive children with negative history of exposure to
VZV.
TABLE 3. Clinical characteristics and laboratory ﬁndings of
study population according to VZV reactivation
VZV
reactivation
n = 7
No
reactivation
n = 32 p-value
Age (mean years  SD) 9.94  4.06 11.97  18.59 0.579a
Male gender, n (%) 4 (57.1) 19 (59.4) 0.617b
PRISM score (mean
score  SD)
7.00  2.71 9.19  5.35 0.134a
VZV history
Past varicella infection (N = 27) 4 (57.1) 23 (71.9)
Vaccinated (N = 6) 0 (0.0) 6 (18.8)
Negative/unknown history
(N = 6)
3 (42.8) 3 (9.4)
VZV IgG 6 (85.7) 29 (90.6) 0.698b
Intubation, n (%) 2 (28.6) 10 (31.2) 0.635c
Total days in ICU
(mean days  SD)
8.71  9.72 4.13  6.34 0.270a
Total days fever
(mean days  SD)
11.7  10.4 3.5  4.9 0.030a
Total days on antibiotic
treatment
(mean days  SD)
13.00  9.98 10.28  6.76 0.514a
TNF-a levels 11.0  13.9 13.7  15.0 0.744a
Cortisol levels 950.2  550.4 501.9  365.2 0.059a
aMann–Whitney U-test p-value.
bChi-square p-value.
cFisher’s exact test p-value.
TABLE 1. VZV-DNA viral load in children hospitalized in the ICU presenting with VZV-DNA shedding
No. Age (years) Sex VZV exposure Admission reason Day of detectiona Blood or saliva Viral load (log10 gc/mL)
1 11 F Varicella Medical 15 Blood 5.5
2 13 F Varicella Surgical 1 Blood 5.49
3 15 M Varicella Surgical 1 Saliva 5.3
4 10 M Varicella Surgical 12 Blood 5.78
5 6 F Unknown Trauma 1 Blood 5.54
6 3.4 M Unknown Medical 7 Blood 5
7 1.5 M Unknown Trauma 9 Blood 5.3
11 Saliva 5.6
aDays after ICU admission.
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that viral reactivation is occurring. VZV-DNA has been
detected in peripheral blood of patients with varicella and
HZ and in up to 9% of asymptomatic blood donors, 17% of
cancer patients and 27.3% of elderly subjects [3–5,13,14].
VZV-DNA was less often detected in saliva than in blood
samples (2/131 vs. 6/74, p 0.026) (Table 2). VZV-DNA and
viable virus have also been detected in saliva from asymptom-
atic immunocompetent astronauts, as well as up to 5% of
adults with HIV [6,7,15]. VZV remains latent in multiple
sensory ganglia neurons, cranial nerves and enteric ganglia
[16,17]. Most HZ cases involve the thorax, with only 20%
arising from the trigeminal ganglion [18]. Whether VZV-DNA
in saliva is the result of activation in the trigeminal ganglion or
viraemia needs further exploration [19].
Varicella zoster virus DNA has been detected in the saliva
of 100%, 52% and 59% of patients with acute HZ, Ramsey Hunt
syndrome and zoster sine herpete, respectively [20,21].
Varicella zoster virus DNA was detected less often (17.9%
vs. 33% of children) and later than HSV (6.6 vs. 3.4 days post-
admission, p 0.009). The latter ﬁnding ﬁts with the more
prolonged time to reactivation seen in other scenarios such as
following transplantation [22]. HSV-1 was only detected in
saliva. This is not surprising given that disseminated HSV
infection and viraemia have only been described in neonates
and immunocompromised patients while normal healthy
individuals rarely shed HSV-1 asymptomatically [12,23,24].
Accordingly, we detected HSV-DNA in saliva obtained from
one (2.6%) of our healthy controls. The frequency of HSV-
DNA detection in saliva in our study (33%) was similar to
previous studies [12]. HSV-DNA was detected signiﬁcantly
more often in saliva samples obtained from children admitted
for medical reasons, although they had lower PRISM III scores.
Unlike others we did not ﬁnd an association of intubation with
HSV-DNA detection or HSV viral load in our cohort (data not
shown). As previously reported, HSV antibodies were a poor
predictor of HSV reactivation, suggesting low sensitivity of the
Elisa test used [24].
For the majority of patients, VZV or HSV-1-DNA was
detected only once, as previously described [7]. Three children
shed HSV-1-DNA for 7–9 days, while shedding of virus for
more than 3 days has been reported in up to 10% of healthy
adult patients [24].
The main limitations of this study include the size of the
study population and infrequent sampling. The small sample
size limits interpretation of the observations made. Impor-
tantly, more frequent blood sampling might have provided
valuable additional information regarding our understanding of
VZV reactivation under severe stress. The detection of HSV-1
for a prolonged period (7–9 days) may reﬂect biases in the
study design, because VZV-DNA was mainly detected in blood
samples, which were only collected once a week, whereas
saliva was collected bi-weekly.
However, three potential important new ﬁndings of rele-
vance to clinical management were identiﬁed.
Interestingly, detection of VZV-DNA was independently
associated with longer duration of fever among ICU children.
Whether VZV viraemia caused prolonged fever or vice versa
remains unclear. The clinical implications of endogenous VZV
reactivation need further evaluation. Alternatively, children
with prolonged fever might represent sicker patients in whom
VZV reactivation occurred due to their underlying disease.
Our cohort was comprised of relatively healthy children, only
30% (12/40) of whom were intubated and most of whom had a
short ICU stay (median 2.5 days) (Table 1). In contrast,
asymptomatic reactivation of other herpes-viruses has been
described in immunocompetent adult ICU patients [9,12,25]
and has been associated with more severe morbidity and
mortality [25]. We did not ﬁnd an association of VZV or HSV-
1 viral DNA load with clinical outcome. Herpes-virus reacti-
vation was not associated with an increased severity score
(PRISM III) on admission; however, detection of VZV-DNA
was weakly associated with higher admission cortisol levels.
While this ﬁnding needs to be veriﬁed with a larger cohort, it
supports the hypothesis that stress is a trigger for VZV
reactivation in immunocompetent children.
Secondly, the mode of primary VZV exposure may have
inﬂuenced whether VZV reactivation occurred. None of six
children immunized with the Oka vaccine had reactivated VZV.
Although vaccinated children were not found to present a
signiﬁcantly reduced risk of VZV reactivation compared with
those after natural infection (symptomatic and/or subclinical),
this is possibly due to our main study limitation, the small
number of children examined. Decreased incidence of HZ
among vaccinees has been reported, possibly because skin
infection is reduced and hence the ability to establish latency is
diminished [26,27]. However, the Oka strain can establish a
latent infection, as evidenced by the detection of Oka VZV-
DNA in the ganglia of vaccinated children on autopsy [17].
Therefore, larger studies are needed to examine whether
vaccinees are less prone to ‘asymptomatic’ VZV reactivation.
Interestingly, wild-type VZV-DNA was more commonly
detected in whole blood (3/6 children, 3/11 blood samples)
from children with subclinical infection than that from those
with a history of chickenpox (4/27 children, 3/51 blood
samples). While only weakly associated, it is possible that
subclinical chickenpox was associated with lower levels of
viraemia and associated cellular immunity, predisposing these
children to greater risk of reactivation under stress (Table 2).
Finally, reactivation of both HSV-1 and VZV in a single
individual was not documented. HSV and VZV have been
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simultaneously detected in skin lesions from immunocompe-
tent and immunocompromised subjects, as well as in autopsied
cranial and cervical ganglia [28–30]. However, a study of
asymptomatic salivary viral shedding also failed to detect both
viruses in the same sample [31]. This observation needs
further investigation with a larger study.
In conclusion, this study provides the ﬁrst evidence that
VZV reactivation occurs among ICU hospitalized immuno-
competent children under severe stress and that reactivation
is associated with a prolonged course of fever during
hospitalization. VZV-DNA was not detected in children
vaccinated against varicella but was more common in those
with subclinical primary infection. Although the clinical signif-
icance of these ﬁndings needs further investigation, they may
have important implications for susceptible patients and staff,
especially if one considers that in temperate regions most
children are exposed to VZV during early childhood and have
VZV-DNA detected in saliva [1,19]. These ﬁndings may also
have implications for the role of endogenous boosting in
maintaining VZV-speciﬁc immunity and long-term protection
against varicella in the era of varicella vaccination.
Authorship/Contribution
VP and JB are responsible for the conception of the study. All
authors made a substantial contribution to the design of the
study and interpretation of data. EC performed the data
analysis. VP prepared the ﬁrst draft of the manuscript. All
authors critically revised the manuscript and have approved
the ﬁnal version to be published.
Acknowledgements
The authors are grateful to all of the study participants and
their parents as well as to the ICU staff.
Transparency Declaration
VP has received consultation fees from GSK. MQ and JL were
funded by an SPMSD investigator grant to JB. For the remaining
authors no conﬂicts of interest were declared. This work was
supported in part by the Medical Research Council (grant no
G0700814) and by a Small Grant from the European Society of
Pediatric Infectious Diseases (ESPID). JB receives funding from
the NIHR UCL/UCLH Comprehensive Biomedical Research
Centre. We acknowledge the infrastructure support from the
MRC Centre for Medical Molecular Virology.
References
1. Bonanni P, Breuer J, Gershon A et al. Varicella vaccination in Europe–
taking the practical approach. BMC Med 2009; 7: 26.
2. Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Grifﬁths
PD. Advances in the understanding of the pathogenesis and epidemi-
ology of herpes zoster. J Clin Virol 2010; 48 (Suppl 1): S2–S7.
3. Devlin ME, Gilden DH, Mahalingam R, Dueland AN, Cohrs R.
Peripheral blood mononuclear cells of the elderly contain varicella-
zoster virus DNA. J Infect Dis 1992; 165: 619–622.
4. QuinlivanML, Ayres KL, Kelly PJ et al. Persistence of varicella-zoster virus
viraemia in patients with herpes zoster. J Clin Virol 2011; 50: 130–135.
5. Schunemann S, Mainka C, Wolff MH. Subclinical reactivation of
varicella-zoster virus in immunocompromised and immunocompetent
individuals. Intervirology 1998; 41: 98–102.
6. Cohrs RJ, Mehta SK, Schmid DS, Gilden DH, Pierson DL. Asymptom-
atic reactivation and shed of infectious varicella zoster virus in
astronauts. J Med Virol 2008; 80: 1116–1122.
7. Mehta SK, Cohrs RJ, Forghani B, Zerbe G, Gilden DH, Pierson DL.
Stress-induced subclinical reactivation of varicella zoster virus in
astronauts. J Med Virol 2004; 72: 174–179.
8. Pollack MM, Patel KM, Ruttimann UE. The Pediatric Risk of Mortality
III–Acute Physiology Score (PRISM III-APS): a method of assessing
physiologic instability for pediatric intensive care unit patients. J Pediatr
1997; 131: 575–581.
9. Simoons-Smit AM, Kraan EM, Beishuizen A, Strack van Schijndel RJ,
Vandenbroucke-Grauls CM. Herpes simplex virus type 1 and respira-
tory disease in critically-ill patients: real pathogen or innocent
bystander? Clin Microbiol Infect 2006; 12: 1050–1059.
10. Quinlivan ML, Gershon AA, Al Bassam MM et al. Natural selection for
rash-forming genotypes of the varicella-zoster vaccine virus detected
within immunized human hosts. Proc Natl Acad Sci USA 2007; 104: 208–
212.
11. Quinlivan ML, Gershon AA, Steinberg SP, Breuer J. Rashes occurring
after immunization with a mixture of viruses in the Oka vaccine
are derived from single clones of virus. J Infect Dis 2004; 190: 793–
796.
12. Bruynseels P, Jorens PG, Demey HE et al. Herpes simplex virus in the
respiratory tract of critical care patients: a prospective study. Lancet
2003; 362: 1536–1541.
13. Kimura H, Kido S, Ozaki T et al. Comparison of quantitations of viral
load in varicella and zoster. J Clin Microbiol 2000; 38: 2447–2449.
14. Quinlivan ML, Ayres K, Ran H et al. Effect of viral load on the outcome
of herpes zoster. J Clin Microbiol 2007; 45: 3909–3914.
15. Wang CC, Yepes LC, Danaher RJ et al. Low prevalence of varicella
zoster virus and herpes simplex virus type 2 in saliva from human
immunodeﬁciency virus-infected persons in the era of highly active
antiretroviral therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod
2010; 109: 232–237.
16. Chen JJ, Gershon AA, Li Z, Cowles RA, Gershon MD. Varicella zoster
virus (VZV) infects and establishes latency in enteric neurons. J
Neurovirol 2011; 17: 578–589.
17. Gershon AA, Chen J, Davis L, Krinsky C, Cowles R, Gershon MD.
Distribution of latent varicella zoster virus in sensory ganglia and gut
after vaccination and wild-type infection: evidence for viremic spread.
In: 34th International Herpesvirus Workshop, Ithaca, NY, 2009.
18. Hope-Simpson RE. The nature of herpes zoster: a long-term study and
a new hypothesis. Proc R Soc Med 1965; 58: 9–20.
19. Gershon AA. The history and mystery of VZV in saliva. J Infect Dis
2011; 204: 815–816.
20. Furuta Y, Ohtani F, Sawa H, Fukuda S, Inuyama Y. Quantitation of
varicella-zoster virus DNA in patients with Ramsay Hunt syndrome
and zoster sine herpete. J Clin Microbiol 2001; 39: 2856–2859.
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, E245–E251
E250 Clinical Microbiology and Infection, Volume 19 Number 5, May 2013 CMI
21. Nagel MA, Choe A, Cohrs RJ et al. Persistence of varicella zoster virus
DNA in saliva after herpes zoster. J Infect Dis 2011; 204: 820–824.
22. Meier JL, Straus SE. Comparative biology of latent varicella-zoster virus
and herpes simplex virus infections. J Infect Dis 1992; 166 (Suppl 1):
S13–S23.
23. Kaufman HE, Azcuy AM, Varnell ED, Sloop GD, Thompson HW, Hill
JM. HSV-1 DNA in tears and saliva of normal adults. Invest Ophthalmol
Vis Sci 2005; 46: 241–247.
24. Miller CS, Danaher RJ. Asymptomatic shedding of herpes simplex virus
(HSV) in the oral cavity. Oral Surg Oral Med Oral Pathol Oral Radiol Endod
2008; 105: 43–50.
25. Osawa R, Singh N. Cytomegalovirus infection in critically ill patients: a
systematic review. Crit Care 2009; 13: R68.
26. Civen R, Chaves SS, Jumaan A et al. The incidence and clinical
characteristics of herpes zoster among children and adolescents after
implementation of varicella vaccination. Pediatr Infect Dis J 2009; 28:
954–959.
27. Hambleton S, Steinberg SP, Larussa PS, Shapiro ED, Gershon AA. Risk
of herpes zoster in adults immunized with varicella vaccine. J Infect Dis
2008; 197 (Suppl 2): S196–S199.
28. Giehl KA, Muller-Sander E, Rottenkolber M, Degitz K, Volkenandt M,
Berking C. Identiﬁcation and characterization of 20 immunocompetent
patients with simultaneous varicella zoster and herpes simplex virus
infection. J Eur Acad Dermatol Venereol 2008; 22: 722–728.
29. Park HH, Lee MH. Concurrent reactivation of varicella zoster virus and
herpes simplex virus in an immunocompetent child. J Korean Med Sci
2004; 19: 598–600.
30. Richter ER, Dias JK, Gilbert JE 2nd, Atherton SS. Distribution of herpes
simplex virus type 1 and varicella zoster virus in ganglia of the human
head and neck. J Infect Dis 2009; 200: 1901–1906.
31. Miller CS, Berger JR, Mootoor Y, Avdiushko SA, Zhu H, Kryscio RJ.
High prevalence of multiple human herpesviruses in saliva from human
immunodeﬁciency virus-infected persons in the era of highly active
antiretroviral therapy. J Clin Microbiol 2006; 44: 2409–2415.
ª2012 The Authors
Clinical Microbiology and Infection ª2012 European Society of Clinical Microbiology and Infectious Diseases, CMI, 19, E245–E251
CMI Papaevangelou et al. Subclinical VZV reactivation in children E251
